OMERACT 10 patient perspective virtual campus: Valuing health; measuring outcomes in rheumatoid arthritis fatigue, RA sleep, arthroplasty, and systemic sclerosis; and clinical significance of changes in health

Journal of Rheumatology

Volumn 38, Issue 8, 2011, Pages 1728-1734

  Kirwan, John R ^a   Boonen, Annelies ^b   Harrison, Mark J ^c   Hewlett, Sarah E ^d   Wells, George A ^e   Singh, Jasvinder A ^f   Furst, Daniel E ^g   Dworkin, Robert H ^h  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^e UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Fatigue arthroplasty; Outcome measures; Rheumatic diseases

Indexed keywords

GLUCOCORTICOID; INFLIXIMAB;

ARTHROPATHY; CLINICAL DECISION MAKING; COGNITIVE THERAPY; CONFERENCE PAPER; FATIGUE; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HUMAN; OUTCOME ASSESSMENT; OUTCOME MEASURES IN RHEUMATOLOGY; PAIN ASSESSMENT; PATIENT ATTITUDE; POLYARTHRITIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; SLEEP; SYSTEMIC SCLEROSIS;

ARTHRITIS, RHEUMATOID; ARTHROPLASTY; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; FATIGUE; HUMANS; OUTCOME ASSESSMENT (HEALTH CARE); PATIENT SATISFACTION; QUALITY-ADJUSTED LIFE YEARS; RHEUMATOLOGY; SCLERODERMA, SYSTEMIC; SLEEP; TREATMENT OUTCOME;

EID: 79961102662     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.110393     Document Type: Conference Paper

References (42)

1. Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A. Valuing health for clinical and economic decisions: Directions relevant for rheumatologists. J Rheumatol 2011;38:1770-5.
2. Russell LB, Siegel JE, Daniels N, Gold MR, Luce BR, Mandelblatt JS. Cost-effectiveness analysis as a guide to resource allocation in health: roles and limitations. Oxford: Oxford University Press; 1996.
3. Carr AJ, Gibson B, Robinson PG. Measuring quality of life: Is quality of life determined by expectations or experience? BMJ 2001;322:1240-3. (Pubitemid 32453083)
4. Bansback N, Harrison M, Brazier J, Davies L, Kopec J, Marra CA, et al. Health state utility values: a description of their development and application for rheumatic diseases. Arthritis Rheum 2008;59:1018-26. (Pubitemid 351991000)
5. EuroQoL - a new facility for the measurement of health-related quality of life. The EuroQoL Group. Health Policy 1990;16:199-208.
6. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ 2002;21:271-92. (Pubitemid 34143147)
7. Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The validity and responsiveness of generic utility measures in rheumatoid arthritis: a review. J Rheumatol 2008;35:592-602. (Pubitemid 351500053)
8. Dolders MG, Zeegers MP, Groot W, Ament A. A meta-analysis demonstrates no significant differences between patient and population preferences. J Clin Epidemiol 2006;59:653-64. (Pubitemid 43825720)
9. Harrison MJ, Davies LM, Bansback NJ, McCoy MJ, Verstappen SM, Watson K, et al. The comparative responsiveness of the EQ-5D and SF-6D to change in patients with inflammatory arthritis. Qual Life Res 2009;18:1195-205.
10. Marra CA, Rashidi AA, Guh D, Kopec JA, Abrahamowicz M, Esdaile JM, et al. Are indirect utility measures reliable and responsive in rheumatoid arthritis patients? Qual Life Res 2005;14:1333-44. (Pubitemid 40895755)
11. Harrison MJ, Lunt M, Verstappen SM, Watson KD, Bansback NJ, Symmons DP. Exploring the validity of estimating EQ-5D and SF-6D utility values from the Health Assessment Questionnaire in patients with inflammatory arthritis. Health Qual Life Outcomes 2010;8:21.
12. Marra CA, Marion SA, Guh DP, Najafzadeh M, Wolfe F, Esdaile JM, et al. Not all "quality-adjusted life years" are equal. J Clin Epidemiol 2007;60:616-24. (Pubitemid 46711077)
13. Maini R, St. Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, for the ATTRACT Study Group. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Lancet 1999;354;1932-9.
14. Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005;4:201-8. (Pubitemid 43242208)
15. Gandjour A. Theoretical foundation of patient v. population preferences in calculating QALYs. Med Decis Making 2010;30:E57-63.
16. Brazier J, Akehurst R, Brennan A, Dolan P, Claxton K, McCabe C, et al. Should patients have a greater role in valuing health states? Appl Health Econ Health Policy 2005;4:201-8. (Pubitemid 43242208)
17. Staley K. Exploring impact: Public involvement in NHS, public health and social care research. INVOLVE, Eastleigh; 2009. [Internet. Accessed April 13, 2011.] Available from: http://www.invo.org.uk/pdfs/Involve-Exploring- Impactfinal28.10.09.pdf
18. Kirwan J, Newman S, Tugwell P, Wells G, Hewlett S, Idzera L, et al. Progress on incorporating the patient perspective in outcome assessment in rheumatology and the emergence of Life Impact Measures at OMERACT 9. J Rheumatol 2009;36:2071-6.
19. Nicklin J, Cramp F, Kirwan J, Urban M, Hewlett S. Collaboration with patients in the design of patient reported outcome measures: Capturing the experience of fatigue in rheumatoid arthritis. Arthritis Care Res 2010;62:1552-8.
20. Nicklin J, Cramp F, Kirwan J, Urban M, Hewlett S. Measuring fatigue in RA: Evaluation of the Bristol RA Fatigue Multi- Dimensional Questionnaire, Visual Analogue and Numerical Rating Scales (BRAF). Arthritis Care Res 2010;62:1559-68.
21. Hewlett S, Almeida C, Kirwan JR, Cramp F, Choy EHS, Chalder T. Non-pharmacological interventions for fatigue in rheumatoid arthritis (Protocol). Cochrane Database Syst Rev 2010;1:CD008322.
22. Almeida C, Hewlett S, Kirwan JR, Cramp F, Chalder T, Choy EHS. Biologic interventions for fatigue in rheumatoid arthritis (Protocol). Cochrane Database Syst Rev 2010;1:CD008334.
23. Hewlett S, Almeida C, Kirwan JR, Cramp F, Choy EHS, Chalder T. Non-pharmacological interventions for fatigue in rheumatoid arthritis (Protocol) Cochrane Database Syst Rev 2010;1:CD008322.
24. Hewlett S, Ambler N, Knops B, Cliss A, Almeida C, Pope D, et al. Reducing the impact of rheumatoid arthritis fatigue: A randomized controlled trial of cognitive behavioural therapy [abstract]. Rheumatology 2010;49:OP37.
25. Gossec L, Dougados M, Rincheval N, Balanescu A, Boumpas DT, Canadelo S, et al. Elaboration of the preliminary Rheumatoid Arthritis Impact of Disease (RAID) score: a EULAR initiative. Ann Rheum Dis 2009;68:1680-5.
26. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. What outcomes from pharmacological treatments are important to people with rheumatoid arthritis? Creating the basis of a patient core set. Arthritis Care Res 2010;62:640-6.
27. Sanderson T, Morris M, Calnan M, Richards P, Hewlett S. Patient perspective of measuring treatment efficacy: The Rheumatoid Arthritis Patient Priorities for Pharmacological Interventions outcomes. Arthritis Care Res 2010;62:647-56.
28. Nikolaus S, Bode C, Taal E, van de Laar MA. New insights into the experience of fatigue among patients with rheumatoid arthritis: a qualitative study. Ann Rheum Dis 2010;69:895-7.
29. Wells GA, Li T, Kirwan JR, Peterson J, Aletaha D, Boers M, et al. Assessing quality of sleep in patients with rheumatoid arthritis. J Rheumatol 2009;36:2077-86.
30. Hays RD, Stewart AL. Sleep measures. In: Stewart AL, Ware JE, editors. Measuring function and well being: The Medical Outcomes Study approach. Durham, NC: Duke University Press; 1992:235-59.
31. Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. Ann Rheum Dis 2010;69:1768-73.
32. Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster JY. Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am 2004;86:963-74. (Pubitemid 38619796)
33. Kane RL, Saleh KJ, Wilt TJ, Bershadsky B. The functional outcomes of total knee arthroplasty. J Bone Joint Surg Am 2005;87:1719-24. (Pubitemid 41061189)
34. Riddle DL, Stratford PW, Bowman DH. Findings of extensive variation in the types of outcome measures used in hip and knee replacement clinical trials: a systematic review. Arthritis Rheum 2008;59:876-83. (Pubitemid 351847572)
35. Singh J, Sloan JA, Johanson NA. Challenges with health-related quality of life assessment in arthroplasty patients: problems and solutions. J Am Acad Orthop Surg 2010;18:72-82.
36. Furst DE. Outcome measures in rheumatologic clinical trials and systemic sclerosis. Rheumatology 2008;47 Suppl 5:v29-30.
37. Khanna D, Distler O, Avouac J, Behrens F, Clements PJ, Denton C, et al. Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS). J Rheumatol 2009;36:2356-61.
38. Avouac J, Walker U, Tyndall A, Kahan A, Matucci-Cerinic M, Allanore Y, et al. Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database. J Rheumatol 2010;37:1488-501.
39. Khanna D, Seibold JR, Wells A, Distler O, Allanore Y, Denton C, et al. Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design. Curr Rheumatol Rev 2010;6:138-44.
40. Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT Recommendations. Pain 2009;9:105-21. (Pubitemid 351147828)
41. Dworkin RH, Turk DC, McDermott MP, Peirce-Sandner S, Burke LB, Cowan P, et al. Interpreting the clinical importance of group differences in chronic pain clinical trials: IMMPACT recommendations. Pain 2009;146:238-44.
42. Kirwan JR. Minimum clinically important difference: The crock of gold at the end of the rainbow? J Rheumatol 2001;28:881-6.